Dorothee Nickles

Bioinformatics Institute — Singapore

Medicine · Health Sciences

21h-index11.7kcitations117works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(49), CAR-T cell therapy research(30), Immune Cell Function and Interaction(23), Monoclonal and Polyclonal Antibodies Research(20), Immune cells in cancer(20)

Publications117 total

Characterization of an anti-STEAP1 T-Cell Dependent Bispecific Antibody for the Treatment of Prostate Cancer and Associated Toxicity in Cynomolgus Monkeys
Toxicological Sciences·2026
Transcription factor Zfx regulates tumor’s evasion to T cell killing in immunotherapy
iScience·2025Open Access
556 Transcription factor Zfx regulates tumor’s evasion to T cell killing in immunotherapy
Regular and Young Investigator Award Abstracts·2024Open Access
ZBP1 and TRIF trigger lethal necroptosis in mice lacking caspase-8 and TNFR1
Cell Death and Differentiation·2024· 24 citedOpen Access
Supplementary Figure 4 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 5 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 5 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Table 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Table 2 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 4 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 3 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Data from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 2 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Data from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Table 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
Supplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Rafael Cubas(14), Yagai Yang(13), Huizhong Xiong(11), Stephanie Mittman(11), Ryan Rodriguez(11), Марина Москаленко(11), Patricia Pacheco-Sanchez(11), Ira Mellman(10), Priti S. Hegde(10), Sanjeev Mariathasan(9), Sergio E. Baranzini(9), Suchit Jhunjhunwala(7), Zora Modrušan(7), Edward E. Kadel(6), Richard Bourgon(6), Oded Foreman(6), Justin Elstrott(6), Alex T. Ritter(6), Sören Müller(6), Teresita L. Arenzana(6)